ClinicalTrials.gov
public full text
Public Domain
Association Between Plasma Melatonin and No-reflow
ST-segment elevation myocardial infarction (STEMI) is an acute manifestation of coronary heart disease, remaining a frequent cause of death. A better understanding of risk factors and pathogenic mechanisms underlying STEMI may help improve the prognosis and life quality of these patients. Melatonin is the chief indoleamine produced by the pineal gland, and a well-known antioxidant and free radical scavenger. Basic studies have showed that melatonin is associated with myocardial infarction and heart failure. However, no study has evaluated whether melatonin is associated with adverse clinical outcomes in STEMI patients.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effects of Melatonin on Reperfusion Injury#849834
- Melatonin on Coronary Artery Calcification#1126034
- Study MIPAE - Melatonin and Essential Arterial Hypertension#876873
- Effectiveness of Early Cardiorespiratory Rehabilitation Combined With Melatonin Supplementation During the Inpatient Period After Acute Myocardial Infarction: a Pilot Study#235214
- Dose Assessment of Melatonin in Sepsis Trial#1126987
Record · ID 1087521
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive